Clinical Trials
3 trialsNCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05932199 2025-09-25
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Baylor College of Medicine
Phase 1/2 Recruiting
NCT02592551 2022-09-29
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Baylor College of Medicine
Phase 2 Completed